Neurogene Inc.NGNE

$31.53+0.74 (+2.40%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$703M

Small-cap

-87%

2016 — today

10-Year Price

-78%

2016 — today

52-Week Range

$14.95$34.37

Current $31.53· 85%

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

Valuation in context

P/E ratio

-6.3

N/A

Not meaningful — company is unprofitable

P/B ratio

3.0

Below average

Below the 10-year average

FCF Yield

-11.8%

Below average

Below the 10-year average

Free · No credit card needed

Get alerted when NGNE is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.